Healthcare
STAAR Surgical Company(STAA)
Live Price
Offline$29.12
-0.34% today
1Y Change
+70.08%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $1.35B
- Revenue Growth
- -23.7%
- EPS Growth
- -295.1%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
STAAR Surgical Company (STAA) is a Healthcare stock with a market cap of $1.35B and listed on NASDAQ. The stock last traded around $29.12 and up 70.1% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -23.7%, EPS growth of -295.1%, a dividend yield of 0.0%. What stands out right now is revenue -23.7%, EPS -295.1%, free cash flow -422.2% with operating margin -33.3% and ROIC -19.5%. Valuation sits in the middle of the pack at price/sales 5.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines STAA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-23.7% vs +7.6% peer median
Operating Margin
Below sector median
-33.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -23.7% and EPS is at -295.1%, with operating margin around -33.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -1.7% | +5.9% | +7.6% |
2026 Mar 3, 2026 | -211.1% | +1.6% | -8.9% | -1.2% |
2025 Nov 5, 2025 | +155.6% | +5.5% | +2.4% | +5.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STAA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STAA Max Drawdown
-43.65%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STAA and SPY.
Company Overview
STAAR Surgical Company
NASDAQ Global Market
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
- Leadership
- Warren Foust
- IPO Date
- Feb 24, 1992
- Employees
- 1.2k
- Street Address
- 25651 Atlantic Ocean Drive
- Mailing
- Lake Forest, CA, 92630
- Region
- Lake Forest, CA, US
- Reporting Currency
- USD
- Investor Line
- 626 303 7902
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 5.6
- Price/Book
- 3.9
Growth
- Revenue
- -23.7%
- EPS
- -295.1%
- Free Cash Flow
- -422.2%
Profitability
- Gross Margin
- 75.6%
- Operating Margin
- -33.3%
- Net Margin
- -33.6%
- ROE
- -23.2%
- ROIC
- -19.5%
Balance Sheet
- Debt/Equity
- 0.11
- Current Ratio
- 4.55
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.